Alkermes PLC (ALKS) Receives "Neutral" Rating from Cantor Fitzgerald


's stock had its "neutral" rating restated by analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $51.00 target price on the stock.



from Biotech News